Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas

International Journal of Pharmaceutics

Volumn 458, Issue 2, 2013, Pages 324-333

  Amin, Mohamadreza ^a   Badiee, Ali ^a   Jaafari, Mahmoud Reza ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

C 26 colon carcinoma; Doxorubicin; Liposomes; RGD peptides; Vascular targeting

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID DEXTRO PHENYLALANYL(N METHYL)LYSINE; ARGINYLGLYCYLASPARTIC ACID DEXTRO PHENYLALANYLLYSINE; ARGINYLGLYCYLASPARTIC ACID DEXTRO TYROSYLCYSTEINE; CYCLIC ARGINYLGLYCYLASPARTIC ACID; DOXORUBICIN; INTEGRIN; LIPOSOME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER LOCALIZATION; CELL INTERACTION; COLON CARCINOMA; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DISTRIBUTION; ENDOCYTOSIS; HUMAN; HUMAN CELL; HYDROPHILICITY; IN VITRO STUDY; MOUSE; NONHUMAN; PHARMACOKINETICS; PLASMA CLEARANCE; PRIORITY JOURNAL; UMBILICAL VEIN ENDOTHELIAL CELL;

AMMONIUM SULFATE (PUBCHEM CID: 6097028); C-26 COLON CARCINOMA; CHOLESTEROL (PUBCHEM CID: 5997); DOXORUBICIN; DOXORUBICIN HCL (PUBCHEM CID: 443939); ETHYLENEDIAMINETETRAACETIC ACID (PUBCHEM CID: 6049); HEPES (PUBCHEM CID: 23831); HYDROXYLAMINE HYDROCHLORIDE (PUBCHEM CID: 443297); ISOPROPANOL (PUBCHEM CID: 3776); LIPOSOMES; METHYLPHENAZONIUM METHOSULFATE (PUBCHEM CID: 9285); RGD PEPTIDES; SODIUM AZIDE (PUBCHEM CID: 33557); VASCULAR TARGETING; Α-TOCOPHEROL (PUBCHEM CID: 2116);

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA; CELLS, CULTURED; COLONIC NEOPLASMS; DOXORUBICIN; ENDOCYTOSIS; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LIGANDS; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED BALB C; PEPTIDES, CYCLIC; POLYETHYLENE GLYCOLS; TISSUE DISTRIBUTION;

EID: 84889102624     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.10.018     Document Type: Article

References (44)

1. P. Alessi, C. Ebbinghaus, and D. Neri Molecular targeting of angiogenesis Biochim. Biophys. Acta Rev. Cancer 1654 2004 39 49 (Pubitemid 38230930)
2. Y. Barenholz Liposome application: problems and prospects Curr. Opin. Colloid Interf. Sci. 6 2001 66 77 (Pubitemid 32233069)
3. Y. Barenholz Doxil(R) - the first FDA-approved nano-drug: lessons learned J. Control. Release 160 2012 117 134
4. G.R. Bartlett Phosphorus assay in column chromatography J. Biol. Chem. 234 1959 466 468
5. D.C. Bibby, J.E. Talmadge, M.K. Dalal, S.G. Kurz, K.M. Chytil, S.E. Barry, D.G. Shand, and M. Steiert Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice Int. J. Pharm. 293 2005 281 290 (Pubitemid 40381100)
6. A. Bikfalvi, and R. Bicknell Recent advances in angiogenesis, anti-angiogenesis and vascular targeting Trends Pharmacol. Sci. 23 2002 576 582 (Pubitemid 35375803)
7. E.M. Bolotin, R. Cohen, L.K. Bar, N. Emanuel, S. Ninio, D.D. Lasic, and Y. Barenholz Ammonium sulfate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandoliposomes J. Liposome Res. 4 1994 455 479 (Pubitemid 24130556)
8. 125I-labeled RGD peptide are improved by PEGylation Nucl. Med. Biol. 31 2004 11 19 (Pubitemid 38115121)
9. A. Corti, F. Pastorino, F. Curnis, W. Arap, M. Ponzoni, and R. Pasqualini Targeted drug delivery and penetration into solid tumors Med. Res. Rev. 32 2012 1078 1091
10. M.A. Dechantsreiter, E. Planker, B. Matha, E. Lohof, G. Holzemann, A. Jonczyk, S.L. Goodman, and H. Kessler N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists J. Med. Chem. 42 1999 3033 3040 (Pubitemid 29384038)
11. J. Denekamp Vascular endothelium as the vulnerable element in tumours Acta Radiol. Oncol. 23 1984 217 225 (Pubitemid 15072794)
12. I. Dijkgraaf, J.A. Kruijtzer, C. Frielink, A.C. Soede, H.W. Hilbers, W.J. Oyen, F.H. Corstens, R.M. Liskamp, and O.C. Boerman Synthesis and biological evaluation of potent alphavbeta3-integrin receptor antagonists Nucl. Med. Biol. 33 2006 953 961 (Pubitemid 44791955)
13. P.K. Dubey, V. Mishra, S. Jain, S. Mahor, and S.P. Vyas Liposomes modified with cyclic RGD peptide for tumor targeting J. Drug Target. 12 2004 257 264 (Pubitemid 39294866)
14. M.E. Eichhorn, S. Strieth, and M. Dellian Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives Drug Resist. Updat. 7 2004 125 138 (Pubitemid 38736065)
15. A. Gabizon, H. Shmeeda, A.T. Horowitz, and S. Zalipsky Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates Adv. Drug Deliv. Rev. 56 2004 1177 1192 (Pubitemid 38496514)
16. A. Garg, A.W. Tisdale, E. Haidari, and E. Kokkoli Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide Int. J. Pharm. 366 2009 201 210
17. K.E. Gottschalk, and H. Kessler The structures of integrins and integrin-ligand complexes: implications for drug design and signal transduction Angew. Chem. Int. Ed. Eng. 41 2002 3767 3774 (Pubitemid 35277998)
18. D. Hauzenberger, J. Klominek, and K.G. Sundqvist Functional specialization of fibronectin-binding beta 1-integrins in T lymphocyte migration J. Immunol. 153 1994 960 971 (Pubitemid 24228487)
19. D. Heckmann, and H. Kesster Design and chemical synthesis of integrin ligands Integrins 426 2007 463 503
20. D. Heckmann, A. Meyer, L. Marinelli, G. Zahn, R. Stragies, and H. Kessler Probing integrin selectivity: rational design of highly active and selective ligands for the alpha 5 beta 1 and alpha v beta 3 integrin receptor Angew. Chem. Int. Ed. Eng. 46 2007 3571 3574 (Pubitemid 46973460)
21. U. Hersel, C. Dahmen, and H. Kessler RGD modified polymers: biomaterials for stimulated cell adhesion and beyond Biomaterials 24 2003 4385 4415 (Pubitemid 36960136)
22. P. Holig, M. Bach, T. Volkel, T. Nahde, S. Hoffmann, R. Muller, and R.E. Kontermann Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells Protein Eng. Des. Sel. 17 2004 433 441 (Pubitemid 39280045)
23. A.T. Horowitz, Y. Barenholz, and A.A. Gabizon In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release Biochim. Biophys. Acta 1109 1992 203 209
24. Z. Huang, M.R. Jaafari, and F.C. Szoka Jr. Disterolphospholipids: nonexchangeable lipids and their application to liposomal drug delivery Angew. Chem. Int. Ed. Eng. 48 2009 4146 4149
25. Z. Huang, and F.C. Szoka Jr. Sterol-modified phospholipids: cholesterol and phospholipid chimeras with improved biomembrane properties J. Am. Chem. Soc. 130 2008 15702 15712
26. J. Lehtinen, A. Magarkar, M. Stepniewski, S. Hakola, M. Bergman, T. Rog, M. Yliperttula, A. Urtti, and A. Bunker Analysis of cause of failure of new targeting peptide in PEGylated liposome: molecular modeling as rational design tool for nanomedicine Eur. J. Pharm. Sci. 46 2012 121 130
27. N. Maeda, Y. Takeuchi, M. Takada, Y. Sadzuka, Y. Namba, and N. Oku Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome J. Control. Release 100 2004 41 52 (Pubitemid 39445984)
28. C. Mas-Moruno, F. Rechenmacher, and H. Kessler Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation Anticancer Agents Med. Chem. 10 2010 753 768
29. A. Mitra, T. Coleman, M. Borgman, A. Nan, H. Ghandehari, and B.R. Line Polymeric conjugates of mono- and bi-cyclic alpha(V)beta(3) binding peptides for tumor targeting J. Control. Release 114 2006 175 183 (Pubitemid 44291848)
30. S.M. Moghimi, and H.M. Patel Serum opsonins and phagocytosis of saturated and unsaturated phospholipid liposomes Biochim. Biophys. Acta 984 1989 384 387 (Pubitemid 19222130)
31. L.E. Odekon, M.B. Frewin, P. Del Vecchio, T.M. Saba, and P.W. Gudewicz Fibronectin fragments released from phorbol ester-stimulated pulmonary artery endothelial cell monolayers promote neutrophil chemotaxis Immunology 74 1991 114 120
32. N. Oku, T. Asai, K. Watanabe, K. Kuromi, M. Nagatsuka, K. Kurohane, H. Kikkawa, K. Ogino, M. Tanaka, D. Ishikawa, H. Tsukada, M. Momose, J. Nakayama, and T. Taki Anti-neovascular therapy using novel peptides homing to angiogenic vessels Oncogene 21 2002 2662 2669 (Pubitemid 34478324)
33. J. Qin, D. Chen, H. Hu, Q. Cui, M. Qiao, and B. Chen Surface modification of RGD-liposomes for selective drug delivery to monocytes/neutrophils in brain Chem. Pharm. Bull. (Tokyo) 55 2007 1192 1197 (Pubitemid 47344972)
34. E. Ruoslahti The RGD story: a personal account Matrix Biol. 22 2003 459 465 (Pubitemid 37518305)
35. M. Salvati, F.M. Cordero, F. Pisaneschi, F. Melani, P. Gratteri, N. Cini, A. Bottoncetti, and A. Brandi Synthesis, SAR and in vitro evaluation of new cyclic Arg-Gly-Asp pseudopentapeptides containing a s-cis peptide bond as integrin alphavbeta3 and alphavbeta5 ligands Bioorg. Med. Chem. 16 2008 4262 4271 (Pubitemid 351539049)
36. L. Sancey, V. Ardisson, L.M. Riou, M. Ahmadi, D. Marti-Batlle, D. Boturyn, P. Dumy, D. Fagret, C. Ghezzi, and J.P. Vuillez In vivo imaging of tumour angiogenesis in mice with the alpha(v)beta (3) integrin-targeted tracer 99mTc-RAFT-RGD Eur. J. Nucl. Med. Mol. Imaging 34 2007 2037 2047 (Pubitemid 350212119)
37. R.M. Schiffelers, G.A. Koning, T.L.M. ten Hagen, M.H.A.M. Fens, A.J. Schraa, A.N.P.C.A. Janssen, R.J. Kok, G. Molema, and G. Storm Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin J. Control. Release 91 2003 115 122 (Pubitemid 37288882)
38. C. Schliemann, and D. Neri Antibody-based targeting of the tumor vasculature Biochim. Biophys. Acta Rev. Cancer 1776 2007 175 192 (Pubitemid 350061071)
39. T. Schluep, J. Hwang, J. Cheng, J.D. Heidel, D.W. Bartlett, B. Hollister, and M.E. Davis Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models Clin. Cancer Res. 12 2006 1606 1614
40. P. Tardi, M.B. Bally, and T.O. Harasym Clearance properties of liposomes involving conjugated proteins for targeting Adv. Drug Deliv. Rev. 32 1998 99 118 (Pubitemid 28277178)
41. K. Temming, R.M. Schiffelers, G. Molema, and R.J. Kok RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature Drug Resist. Updat. 8 2005 381 402 (Pubitemid 43358061)
42. X.B. Xiong, Y. Huang, W.L. Lu, X. Zhang, H. Zhang, T. Nagai, and Q. Zhang Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic J. Control. Release 107 2005 262 275 (Pubitemid 41316289)
43. X.B. Xiong, Y. Huang, W.L. Lu, X. Zhang, H. Zhang, T. Nagai, and Q. Zhang Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo J. Pharm. Sci. 94 2005 1782 1793 (Pubitemid 41360872)
44. S. Zitzmann, V. Ehemann, and M. Schwab Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo Cancer Res. 62 2002 5139 5143 (Pubitemid 35024582)